FY2025 EPS Estimates for MeiraGTx Cut by Chardan Capital

MeiraGTx Holdings plc (NASDAQ:MGTX - Free Report) - Research analysts at Chardan Capital decreased their FY2025 earnings per share (EPS) estimates for shares of MeiraGTx in a report issued on Wednesday, May 14th. Chardan Capital analyst D. Gataulin now expects that the company will post earnings of ($1.05) per share for the year, down from their previous estimate of $0.25. Chardan Capital currently has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for MeiraGTx's current full-year earnings is ($1.48) per share. Chardan Capital also issued estimates for MeiraGTx's FY2026 earnings at ($0.95) EPS.

Separately, Royal Bank of Canada raised their target price on MeiraGTx from $11.00 to $13.00 and gave the company an "outperform" rating in a report on Monday, March 17th.

MeiraGTx Stock Down 1.0%

MGTX stock opened at $4.99 on Monday. The firm has a market cap of $401.02 million, a PE ratio of -4.12, a PEG ratio of 0.37 and a beta of 1.30. MeiraGTx has a 1 year low of $3.85 and a 1 year high of $8.75. The company has a fifty day simple moving average of $6.29 and a 200 day simple moving average of $6.35. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.13). MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. The business had revenue of $1.93 million during the quarter, compared to analyst estimates of $4.44 million.

Hedge Funds Weigh In On MeiraGTx

Large investors have recently made changes to their positions in the business. Summit Investment Advisors Inc. grew its holdings in MeiraGTx by 106.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,871 shares of the company's stock valued at $30,000 after buying an additional 2,515 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of MeiraGTx by 68.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,975 shares of the company's stock valued at $30,000 after acquiring an additional 2,016 shares during the period. GAMMA Investing LLC grew its stake in shares of MeiraGTx by 3,606.7% in the first quarter. GAMMA Investing LLC now owns 4,448 shares of the company's stock worth $30,000 after acquiring an additional 4,328 shares during the last quarter. CWM LLC grew its stake in shares of MeiraGTx by 1,737.7% in the first quarter. CWM LLC now owns 8,674 shares of the company's stock worth $59,000 after acquiring an additional 8,202 shares during the last quarter. Finally, Ieq Capital LLC bought a new position in MeiraGTx during the first quarter worth $83,000. Institutional investors and hedge funds own 67.48% of the company's stock.

Insider Buying and Selling

In other MeiraGTx news, CEO Alexandria Forbes sold 47,500 shares of the company's stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $5.34, for a total transaction of $253,650.00. Following the completion of the sale, the chief executive officer now directly owns 1,408,983 shares in the company, valued at $7,523,969.22. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Richard Giroux sold 24,000 shares of the firm's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $6.00, for a total value of $144,000.00. Following the completion of the sale, the chief financial officer now directly owns 882,494 shares in the company, valued at approximately $5,294,964. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.50% of the company's stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.